Support By : Li-lab
| PATHWAY_NAME | REACTOME_ID | KEGG_ID | DRUG_NAME | PUBCHEM_CID | Datasource |
|---|---|---|---|---|---|
| Regulation of actin cytoskeleton | R-HSA-392751 | map04810 | benzydamine | 12555 | drug-path |
| Allograft rejection | R-HSA-9679028 | map05330 | benzydamine | 12555 | drug-path |
| Type I diabetes mellitus | R-HSA-5683209 | map04940 | benzydamine | 12555 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | oxytetracycline | 4583 | drug-path |
| Pathways in cancer | R-HSA-9824443 | map05200 | oxytetracycline | 4583 | drug-path |
| Antigen processing and presentation | R-HSA-1236975 | map04612 | oxytetracycline | 4583 | drug-path |
| Olfactory transduction | R-HSA-9751605 | map04740 | oxytetracycline | 4583 | drug-path |
| Systemic lupus erythematosus | R-HSA-977105 | map05322 | oxytetracycline | 4583 | drug-path |
| Neuroactive ligand-receptor interaction | R-HSA-5632681 | map04080 | oxytetracycline | 4583 | drug-path |
| Huntington's disease | R-HSA-1643685 | 0 | oxytetracycline | 4583 | drug-path |
| Cell adhesion molecules (CAMs) | R-HSA-1031690 | 0 | oxytetracycline | 4583 | drug-path |
| Chemokine signaling pathway | R-HSA-168638 | map04062 | oxytetracycline | 4583 | drug-path |
| Parkinson's disease | R-HSA-1643685 | 0 | oxytetracycline | 4583 | drug-path |
| Graft-versus-host disease | R-HSA-1643685 | map05332 | guanethidine | 3518 | drug-path |
| Ubiquitin mediated proteolysis | R-HSA-983153 | map04120 | guanethidine | 3518 | drug-path |
| Hematopoietic cell lineage | R-HSA-173752 | map04640 | guanethidine | 3518 | drug-path |
| Pathways in cancer | R-HSA-9824443 | map05200 | guanethidine | 3518 | drug-path |
| Autoimmune thyroid disease | R-HSA-1643685 | map05320 | guanethidine | 3518 | drug-path |
| Antigen processing and presentation | R-HSA-1236975 | map04612 | guanethidine | 3518 | drug-path |
| Wnt signaling pathway | R-HSA-195721 | map04310 | guanethidine | 3518 | drug-path |